Chronic Idiopathic Constipation With Normal Colon Transit Therapeutics
1. Trulance patent expiration
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Chronic idiopathic constipation; Irritable bowel syndrome with constipation
TRULANCE's oppositions filed in EPO
TRULANCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(3 years ago) | |
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(2 years from now) | |
| US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(3 years ago) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US12146003 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(5 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(6 years from now) | |
| US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US11834521 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(8 years from now) | |
| US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-764) | Jan 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Dosage: TABLET
How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage
TRULANCE family patents
